WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), announced that it will conduct a conference call and audio webcast today at 5:15 p.m. Eastern Daylight Time regarding the Phase 2b trial results for AZD3480 in Alzheimer’s disease that were just announced. Participants from Targacept will include J. Donald deBethizy, Ph.D., President and Chief Executive Officer; Geoffrey C. Dunbar, M.D., Vice President, Clinical Development and Regulatory Affairs; David A. Hosford, M.D., Ph.D., Senior Medical Director; and Alan A. Musso, Vice President and Chief Financial Officer.
